Page
%P
-
Article
Open AccessTotal genomic alteration as measured by SNP-array-based molecular karyoty** is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine
Metaphase cytogenetics (MC) has a major role in the risk stratification of patients with myelodysplastic syndromes (MDSs) and can affect the choice of therapies. Azacitidine (AZA) has changed the outcome of pa...
-
Article
Open AccessEfficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial